Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.

Ultragenyx Pharmaceutical Inc.

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Ultragenyx Pharmaceutical yesterday and set a price target of $105.00. The comp...

Cantor Fitzgerald Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Tactical Resources Corp. ( ($TSE:RARE) ) just unveiled an update. Tactical Resources Corp. announced that it has mailed meeting materials to its sh...

Tactical Resources Corp. Proposes Business Combination to Form New Entity

An update from Tactical Resources Corp. ( ($TSE:RARE) ) is now available. Tactical Resources Corp has secured a US$140 million financing package fr...

Tactical Resources Secures $140M Financing to Boost US Rare Earth Supply

In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $72.00. Issi co...

RBC Capital Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $75.00. The com...

TD Cowen Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical (RARE – Research Report) a...

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Exelixis (EXEL)

Ultragenyx Pharmaceutical ( ($RARE) ) just unveiled an update. On October 30, 2025, Ultragenyx Pharmaceutical announced the dosing of the first pat...

Ultragenyx Begins Dosing in Aurora Study for Angelman Syndrome

Ultragenyx Pharmaceutical, Inc. (($RARE)) announced an update on their ongoing clinical study. Ultragenyx Pharmaceutical Inc. is conducting a follo...

Ultragenyx’s Ongoing Study on UX111: A Potential Game-Changer for MPS IIIA Treatment

Ultragenyx Pharmaceutical, Inc. (($RARE)) announced an update on their ongoing clinical study. Study Overview: Ultragenyx Pharmaceutical Inc. is co...

Market Cap	$59.93M	P/E Ratio	N/A
52W High	$50.00	52W Low	$25.81
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	2.1%	52W Position	32.2%
Overall Score	32	Value Score	40
Quality Score	--	Technical Score	25

EPS Current Est	$-5.79	EPS Next Est	$-4.55
EPS Growth Est	N/A	DPS Growth 3Y	0.0%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RARE	$33.59	+7.73%	1.68M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RARE	$33.59	+7.7%	1.68M
3
4
5
6

RARE

RARE

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Ultragenyx Pharmaceutical Inc. Data in Excel

Get Ultragenyx Pharmaceutical Inc. Data in Excel